Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 3 versus MONISTAT 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 3 versus MONISTAT 5.
MICONAZOLE 3 vs MONISTAT 5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole inhibits fungal cytochrome P450 14α-demethylase (CYP51), thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This leads to increased membrane permeability, leakage of cellular contents, and fungal cell death.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
For vaginal candidiasis: 200 mg (one suppository) intravaginally at bedtime for 3 consecutive days.
Miconazole nitrate 100 mg vaginal suppository inserted once daily at bedtime for 3 days; or 200 mg vaginal suppository once daily at bedtime for 3 days; or 1200 mg vaginal suppository as a single dose.
None Documented
None Documented
Terminal half-life is approximately 24 hours (range 20-30 hours) following topical vaginal application; prolonged in hepatic impairment.
Terminal half-life approximately 24 hours; supports once-daily dosing.
Primarily hepatic metabolism; <1% excreted unchanged in urine; fecal elimination accounts for ~50% of metabolites.
Primarily fecal (90%) as unchanged drug; renal excretion minimal (<1%).
Category A/B
Category C
Antifungal
Antifungal